Search research articles
Contact Us
Filters
Showing results (41-50 of 83) with videos related to
Page
of 9
Sort By:
Crohn'S & Colitis 360
|
February 13, 2023
Development of a New Index to Assess Small Bowel Inflammation Severity in Crohn's Disease Using Magnetic Resonance Enterography
Yoram Bouhnik, Catherine Le Berre, Magaly Zappa, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 17, 2019
Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis
Guillaume Pineton de Chambrun, Aurélien Amiot, Guillaume Bouguen, et al.
Seminars in Arthritis and Rheumatism
|
November 6, 2017
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France
Jérôme Avouac, Anna Moltó, Vered Abitbol, et al.
Therapeutic Advances in Gastroenterology
|
August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Bénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Pauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Alimentary Pharmacology & Therapeutics
|
July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Journal of Crohn'S & Colitis
|
March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis
Mathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Alimentary Pharmacology & Therapeutics
|
February 22, 2020
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients
Constance Chapuis-Biron, Anne Bourrier, Maria Nachury, et al.
Digestive Diseases and Sciences
|
March 5, 2022
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study
Lucas Guillo, Aurélien Amiot, Mélanie Serrero, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 83) with videos related to
Sort By:
Page
of 9
Crohn'S & Colitis 360
|
February 13, 2023
Development of a New Index to Assess Small Bowel Inflammation Severity in Crohn's Disease Using Magnetic Resonance Enterography
Yoram Bouhnik, Catherine Le Berre, Magaly Zappa, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 17, 2019
Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis
Guillaume Pineton de Chambrun, Aurélien Amiot, Guillaume Bouguen, et al.
Seminars in Arthritis and Rheumatism
|
November 6, 2017
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France
Jérôme Avouac, Anna Moltó, Vered Abitbol, et al.
Therapeutic Advances in Gastroenterology
|
August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Bénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Pauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Alimentary Pharmacology & Therapeutics
|
July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Journal of Crohn'S & Colitis
|
March 24, 2017
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis
Mathieu Uzzan, Julien Kirchgesner, Nadia Oubaya, et al.
Alimentary Pharmacology & Therapeutics
|
February 22, 2020
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients
Constance Chapuis-Biron, Anne Bourrier, Maria Nachury, et al.
Digestive Diseases and Sciences
|
March 5, 2022
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study
Lucas Guillo, Aurélien Amiot, Mélanie Serrero, et al.
Page
of 9